FDA Approves Moderna's New COVID Vaccine Amid Tech and Language App Controversies

Moderna's new COVID vaccine, mNEXSPIKE, has been approved by the FDA for specific populations, including adults 65+ and at-risk individuals aged 12-64, offering improved efficacy as a booster. The vaccine targets two segments of the spike protein for longer-lasting immunity and easier distribution, with a safety profile similar to the original. However, approval limitations raise concerns about vaccinating healthy children and adults under 65, especially given the ongoing debate over COVID vaccination policies.